Mica Kanner-Mascolo (via Providence Business News)
CUMBERLAND – Neurotech Pharmaceuticals Inc., a biotech company creating treatments for therapies for chronic eye diseases, has been acquired by Alcon, a publicly traded eye care company out of Switzerland. Alcon purchased Neurotech for $550 million and may make additional payments contingent on possible commercial achievements, the Rhode Island company announced Oct. 20. Under the […]
Economic Activity,
Economy,
Health Services,
Manufacturing,
Subscriber Only,
Alcon,
Cravath,
David Endicott,
Dunn & Crutcher LLP,
ENCELTO,
Gibson,
Goldman Sachs & Co. LLC,
idiopathic macular telangiectasia type 2,
Inc.,
JP Morgan Securities LLC,
Neurotech Pharmaceuticals,
Richard Small,
Swaine & Moore,
U.S. Food and Drug Administration
